EU Health Ministers Discuss Biotechnology and Medicine Supply in Luxembourg

At the Council meeting on Employment, Social Policy, Health and Consumer Affairs (EPSCO) in Luxembourg on June 16, 2026, EU health ministers discussed measures to bolster Europe's standing in pharmaceuticals, biotechnology, and medical devices.

The Council agreed on its negotiating position for provisions on genetically modified microorganisms (GMM) and organ processing, part of the European Biotech Act. These updates aim to foster biotech innovation and modernize regulatory procedures. Simplified processes for certain GMM and updated rules for organ handling and autologous transplants are planned. The European Parliament will subsequently define its position, followed by negotiations on the final legislative text.

Ministers also held an orientation debate on the proposed new EU Biotech Regulation, emphasizing its strategic importance for innovation, competitiveness, and economic resilience. Germany stressed the need for rapid progress and supported measures to shorten and harmonize clinical trial approval processes to enhance Europe's position as a research and innovation hub.

Regarding the Critical Medicines Act, a preliminary political agreement was reached in trilogue negotiations. The legislative proposal aims to strengthen the production of critical medicines in Europe and improve the resilience of supply chains. This includes increased support for EU-based manufacturing, joint procurement procedures, and enhanced information sharing on emergency stockpiles. The goal is to reduce reliance on non-EU manufacturers and ensure the supply of critical medicines like antibiotics and insulin.

The meeting also addressed the implementation of the EU Urban Wastewater Treatment Directive. Germany advocated for a practical and uniform EU-wide implementation that would not hinder efforts to strengthen Europe's industrial base. Discussions also covered the reform of the EU regulation on medical devices, where Germany pushed for easier recertification procedures and faster access to innovative therapies.